The Food and Drug Administration has authorized the emergency use of a coronavirus antibody treatment for certain patients.

On Monday, the FDA approved Eli Lilly & Co’s bamlanivimab drug based on trial data that showed a lowered rate of hospitalizations after a one-time use of the treatment. The treatment has not been authorized for universal use among COVID-19 patients, but it will be given to adults 65 years or old or people over the age of 12 with existing health conditions.